India's Ranbaxy Q1 net profit plunges, lags estimates
MUMBAI May 8 (Reuters) - Ranbaxy Laboratories, India's largest drugmaker by sales, reported a 90 percent drop in first quarter net profit compared to the same year-ago period, when it had exclusive rights to a generic version of cholesterol lowering drug Lipitor in the United States.
Ranbaxy said consolidated net profit fell to 1.26 billion rupees ($23.29 million) in the fiscal first quarter ended March, from 12.47 billion rupees last year. Sales fell 34.2 percent to 24.4 billion rupees.
Analysts, on an average, had estimated a net profit of 1.41 billion rupees on net sales of 26.48 billion rupees, according to I/B/E/S.
Shares in Ranbaxy were down 2.6 percent at 444.6 rupees by 0819 GMT. The stock is down nearly 11 percent this year as compared to 2.4 percent rise in Mumbai market.
($1 = 54.09 rupees) (Reporting by Kaustubh Kulkarni; editing by Miral Fahmy)
- Scots spurn independence, vote to stay in the United Kingdom |
- Scots independence polls close, UK's future in the balance |
- Eight bodies found after attack on Guinea Ebola education team
- Alibaba IPO prices at top of range, raising $21.8 billion |
- Two adults, six children dead in Florida shooting: report